Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.68 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.65 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | TSHR | P16473 | 3/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.64 |
| ▸ | HTR2B | P41595 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | GLA | P06280 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | HTR1A | P08908 | 2/20 | 0.62 |
| ▸ | BLM | P54132 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11746973 | 0.89 | KDM4E (0.80) | KDM4EGPR84MTNR1AMTNR1BCYP2D6 | |
| SCHEMBL2633259 | 0.88 | KDM4E (0.79) | KDM4EGPR84MTNR1AMTNR1BCYP2D6 | |
| SCHEMBL30048580 | 0.88 | KDM4E (0.79) | KDM4EGPR84MTNR1AMTNR1BKMT2A | |
| SCHEMBL8581146 | 0.88 | KDM4E (0.79) | KDM4EGPR84MTNR1AMTNR1BKMT2A | |
| SCHEMBL1395687 | 0.87 | KDM4E (0.77) | KDM4EGPR84MTNR1AMTNR1BCYP2D6 | |
| SCHEMBL2686551 | 0.87 | KDM4E (0.77) | KDM4EGPR84MTNR1AMTNR1BCYP2D6 | |
| SCHEMBL6945002 | 0.87 | KDM4E (0.77) | KDM4EGPR84MTNR1AMTNR1BCYP2D6 | |
| SCHEMBL1461935 | 0.87 | KDM4E (0.77) | KDM4EGPR84MTNR1AMTNR1BCYP2D6 | |
| SCHEMBL15747709 | 0.86 | KDM4E (0.75) | KDM4EGPR84MTNR1AMTNR1BCYP2D6 | |
| SCHEMBL30201905 | 0.86 | KDM4E (0.75) | KDM4EGPR84MTNR1AMTNR1BCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 660 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091067-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | MARVELBIOME INC (US) | 2026-04-02 | — | — | US | claimed |
| US-20250246314-A1 | METHODS FOR THE DETECTION AND TREATMENT OF PANCREATIC DUCTAL ADENOCARCINOMA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-07-31 | — | — | US | claimed |
| EP-4587116-A2 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | MarvelBiome, Inc. (US) | 2025-07-23 | — | — | EP | claimed |
| CN-119792278-A | Application of 5-methoxyindole-3-acetic acid in preparation of medicines for treating depression | 中国人民解放军海军军医大学 | 2025-04-11 | — | — | CN | claimed |
| WO-2025072741-A1 | PRESERVATIVES FOR MOLECULAR SAMPLE ANALYSIS WITH SAMPLE COLLECTION DEVICES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-04-03 | — | — | WO | claimed |
| WO-2025054048-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING LIPID AND CHOLESTEROL METABOLISM ASSOCIATED DISEASES, DISORDERS, AND CONDITIONS | MarvelBiome, Inc. (US) | 2025-03-13 | — | — | WO | claimed |
| CN-119332255-A | Electrochemical synthesis method of arundone derivatives | 云南师范大学 | 2025-01-21 | — | — | CN | claimed |
| CN-117825480-B | Biomarker screening method based on broad-target metabonomics and machine learning, and selected chronic kidney disease biomarker group and application thereof | 武汉大学 | 2024-11-08 | — | — | CN | claimed |
| EP-4440342-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING VAGUS NERVE ASSOCIATED DISEASES, DISORDERS, AND CONDITIONS | MarvelBiome, Inc. (US) | 2024-10-09 | — | — | EP | claimed |
| CN-118714936-A | Methods and uses of microbial compositions, components or metabolites for the treatment of vagal nerve related diseases, disorders and conditions | 奇迹生物公司 | 2024-09-27 | — | — | CN | claimed |
| EP-0850320-A2 | METHODS AND COMPOSITIONS FOR DETECTING BINDING OF LIGAND PAIR USING NON-FLUORESCENT LABEL | DARWIN MOLECULAR CORPORATION (US) | 1998-07-01 | — | — | EP | claimed |
| WO-1997020034-A9 | AUXINIC ANALOGUES OF INDOLE-3-ACETIC ACID | — | 1997-10-16 | — | — | WO | claimed |
| WO-1997027331-A9 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | — | 1997-10-09 | — | — | WO | claimed |
| WO-1997027331-A2 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | RAPIGENE, INC. (US) | 1997-07-31 | — | — | WO | claimed |
| WO-1997027327-A2 | METHODS AND COMPOSITIONS FOR DETECTING BINDING OF LIGAND PAIR USING NON-FLUORESCENT LABEL | RAPIGENE, INC. (US) | 1997-07-31 | — | — | WO | claimed |
| WO-1997020034-A1 | AUXINIC ANALOGUES OF INDOLE-3-ACETIC ACID | LIFE TECHNOLOGIES, INC. (US) | 1997-06-05 | — | — | WO | claimed |
| EP-0214254-B1 | MELATONIN COMPOSITIONS AND USES THEREOF | CELLENA (CELL ENGINEERING) A.G. (CH) | 1992-06-17 | — | — | EP | claimed |
| US-4746674-A | Melatonin compositions and uses thereof | CELLENA (CELL ENGINEERING) AG (CH) | 1988-05-24 | — | — | US | claimed |
| EP-0229131-A1 | USE OF MELATONIN OR RELATED COMPOUNDS FOR THE TREATMENT OF PSORIASIS | CELLENA (CELL ENGENEERING) A.G. (CH) | 1987-07-22 | — | — | EP | claimed |
| WO-1987000432-A2 | USE OF MELATONIN OR RELATED COMPOUNDS FOR THE TREATMENT OF PSORIASIS | CELLENA (CELL ENGINEERING) A.G. (CH) | 1987-01-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091067-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | IAPP, GPR119, FAHD1 | KDM4E 4749/4885GPR84 2136/4885MTNR1A 1708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.